Linda M. Burrell, M.D. Announces Retirement January 29, 2021

Maryland Oncology Hematology is sad to announce that Dr. Linda Burrell will be retiring from practice effective January 29, 2021.   Dr. Burrell has been a pillar of our organization and has provided exceptional patient care to our community for over three decades.  Her clinical excellence and fierce dedication to her patients has established her as one of the leading physicians in our region with Dr. Burrell being recognized as a Top Doctor by Washingtonian Magazine.  More importantly, as you will often hear from her patients, she has set the benchmark for what it means to offer compassionate care in the most difficult of times.

We at Maryland Oncology Hematology will always value Dr. Burrell for her many contributions to our organization. Her hard work, commitment and dedication set an example for all of those around her. While we will miss her greatly, we know that she will continue to be an example we can all follow in both our professional and personal lives. She has made each of us better as individuals and our organization is now a better place because she was a part of it.  She is an irreplaceable member of our team and we all thank her for her years of service.

All of us at Maryland Oncology Hematology look forward to continuing the incredible legacy Dr. Burrell has established in our community. For her existing patients, Dr. Burrell will be coordinating transition of your care.  For her referring physicians, our group will be happy to provide care for your new patient referrals.  Our entire team of physicians and administrators are ready to assist in any way possible and to answer any questions you may have.

Please join us as we celebrate Dr. Burrell and her many accomplishments and wish her well as she begins this next chapter!

 

Thank You,

The Maryland Oncology Hematology Team

Facebooktwitterlinkedinmail

COVID-19 Vaccines for Patients Frequently Asked Questions* (FAQ)

 Q – Which vaccines are available?

  • At this time, two vaccines have been submitted for United States Food and Drug (FDA) Emergency Use Authorization (EUA).
  • Vaccine availability in Maryland will depend on a number of factors including availability as well as vaccine storage capabilities.
  • General information published about each vaccine includes:
    • The Pfizer-BioNTech vaccine: Contains a tiny fragment of the virus’s genetic code made in the lab – called messenger RNA, or mRNA – that codes for a part of the virus called the ‘spike protein’, which sits on the outside of the virus. When the mRNA is injected into the body it can instruct cells to produce these proteins, priming the immune system to be able to recognize and destroy the coronavirus, without exposing the body to the virus itself. This vaccine must be stored at -70°C (-94 oF). This vaccine received FDA EUA approval on December 11, 2020.
  • Moderna vaccine: Like the Pfizer-BioNTech vaccine, the Moderna vaccine contains mRNA that codes for the virus’s spike protein. It can be stored at –20°C

(-4oF; normal freezer temperature) for up to 6 months. This vaccine received FDA EUA approval on December 17, 2020.

 

Q – Which vaccine is most appropriate for me?

  • All the vaccines that are approved by the FDA may be considered.

 

Q – Is the vaccine effective against COVID-19?

  • Detailed information about the effectiveness of each vaccine is available from the respective manufacturers, the FDA and the CDC. Based on clinical trials reviewed by the FDA:
  • The Pfizer vaccine is 95% effective 7 days from the 2nd dose.
  • The Moderna vaccine is 94.5% effective 14 days from the 2nd dose
  • Ongoing studies to assess how well the vaccine works in real-world conditions will continue.

 

Q – How do we know the vaccine is safe?

  • FDA EUA approval requires the same rigorous review of clinical trial data as any other FDA approval.

 

Q – Is the vaccine safe if I am receiving immunotherapy?

  • Based on information studying the influenza vaccines, it appears that vaccines are safe to use in this population of patients. Further information on the COVID-19 vaccines, is not available currently.
  • We will continue to monitor for information and guidance on immunization in special populations including patients on immunotherapy.

Q – Has it been studied/is it safe in immunocompromised individuals? What about in pregnancy and children?

  • The EUA for the Pfizer-BioNTech vaccine is for ages 16 and older.
  • There is no published data in the studies on this; however, we will continue to monitor for published guidance.
  • There have been no published studies to include pregnant women or children <12 yrs. of age. These data points are still being collected.

 

Q – What are the common side effects?

  • Each vaccine manufacturer has identified various possible side effects for its respective vaccine. Information about side effects is available from each manufacturer, but some reported side effects include:
  • Pfizer-BioNTech vaccine
    • Fatigue 3.8%
    • Headache 2.0%
    • Older adults demonstrated fewer side effects
  • Moderna vaccine
    • Injection site pain 2.7%
    • Fatigue 9.7%
    • Myalgia (muscle aches and pains) 8.9%
    • Arthralgia (joint pain) 5.2%
    • Headache 4.5%
    • Pain 4.1%
    • Erythema (superficial redness of the skin) 2.0%

 

Q – Will vaccination help or hinder my response to treatment?

  • There is no published data in the studies on this; however, the decision to receive the vaccine should be made after consultation with your health care provider.

 

Q – What happens if I refuse to receive the vaccine?

  • You as a patient always have the right to refuse any treatment. Your provider should provide adequate education to ensure you can make an informed decision.

 

Q – How soon after I get the vaccine will I become protected from contracting COVID-19?

  • According to the manufacturer, the Pfizer vaccine provides optimal immunity 7 days after the second dose.
  • According to the manufacturer, the Moderna provides optimal immunity 14 days after the second dose.
  • Other COVID-19 precautions such as mask wearing, hand washing, and social distancing should be continued after vaccination. It has not been clearly established at what point after vaccination it is safe to discontinue other COVID-19 precautions.

 

Q – Can I get COVID-19 from getting the vaccine?

  • Per the CDC you cannot develop COVID-19 from vaccines that do not use the live virus.
  • There are several different types of vaccines in development. The goal for each of them is to teach our immune systems how to recognize and fight the virus that causes COVID-19. Sometimes this process can cause symptoms, such as fever. These symptoms are normal and are a sign that the body is building immunity.

 

 

 

*These FAQs consolidate into one document information published or otherwise provided by the Centers for Disease Control, the World Health Organization, the US Food and Drug Administration, professional societies, academic centers, and other experts. Any recommended courses of action made by the foregoing agencies or experts and included in this document are only recommendations.

 

 

 

 

 

 

Facebooktwitterlinkedinmail

Covid19 Vaccine Update

December 22, 2020

To Our Valued MOH Patients:

Many of you have seen in the news that the COVID-19 vaccine approvals were recently
announced by the FDA. The arrival of vaccines is good news in the fight to defeat COVID-19,
but now the challenge begins in the distribution and administration of the vaccine. Although
the Maryland Department of Health has a draft mass vaccination plan (click here), MOH has not
been provided information regarding COVID-19 vaccine availability for our practice and
patients.

As frontline caregivers, our goal is to protect the health and well being of our patients, staff and
communities. We will continue to monitor the situation closely and keep you updated and
informed as more information becomes available on the COVID-19 vaccine via our website.
Please remember that until the population has been broadly immunized, we encourage you to
continue to protect yourself and others by wearing a mask, maintaining social distancing and
washing your hands.

Know that your health and safety continues to be our top priority and we will get through this
together.

Thank you and Happy Holidays.

Joseph Haggerty MD

President

 

Jenny Elrod MSN, RN

Director Clinical Services
Maryland Oncology Hematology

Facebooktwitterlinkedinmail

Office Weather Updates

Columbia: Columbia Office will be closing today at 2:30pm.  The office will reopen Thursday, December 17th at 10:30am.

Frederick & Mt Airy:  Frederick and Mt. Airy locations will be closing at 1pm today. Opening 11am Thursday, December 17th

Rockville, Germantown & Bethesda:  will be closing at 2:30pm today. Opening at 10pm Thursday, December 17th

Annapolis:  Opening at 10pm Thursday, December 17th

Facebooktwitterlinkedinmail

Oncology Radio now Available on your Android Device

Maryland Oncology Hematology‘s podcast “Oncology Radio” now has an application available in the Google Play store for anyone with an Android device. Get updated when a new episode airs and listen to old episodes right from your mobile device. You now have access to some of the top Oncology information from some of the leading oncologists in the area and across the nation. Oncology Radio broadcasts a new episode on the 1st and 15th of every month at 8 PM Est. Listen as one of Maryland Oncology Hematology’s physicians interview their guests about cancer research, cancer screenings, non-profits, clinical trials, and the history and statistics of cancers that many are struggling with. Follow the link that will take you directly to the Google Play store and download the Oncology Radio application today.

 

Download Here: CLICK

 

 

 

Facebooktwitterlinkedinmail

Maryland Oncology Hematology and The US Oncology Network Welcome Cynthia Plate M.D. F.A.C.S, Specialist In Breast Surgery

Dr. Plate brings a new line of treatment services to the clinic, offering patients cutting-edge breast preservation techniques

 

Silver Spring, MD- November, 2020 Maryland Oncology Hematology, the premier provider of cancer services in the Maryland region, announced today it has added a breast surgical oncologist to the practice, enhancing the comprehensive multidisciplinary care it provides to breast patients. Cynthia Plate M.D. F.A.C.S specializes in breast surgery and has extensive training and experience in the field. MOH has been serving cancer patients in the Maryland area for over 40 years, providing patients convenient access to leading cancer experts and the most advanced cancer therapies available today.

Dr. Plate has many years of rigorous education, training, and experience focusing on breast disease and surgery, providing her with a superior understanding of breast cancer biology, genetics, and advanced oncoplastic surgical techniques and breast preservation procedures. By adding Dr. Plate to the practice, MOH’s new White Oak Cancer Center enhances its ability to offer multidisciplinary team care for all types of complex breast issues, including benign breast disease, malignancies, and management of high-risk patients. Seamless high-quality care is provided by a collaborative team of specialists in breast surgery, medical and radiation oncology, diagnostic imaging, pathology, genetic risk evaluation, and supportive care.

“Dr. Plate shares our passion of providing exceptional multidisciplinary cancer care, and we are delighted to have her join our growing practice” said Dr. Joseph Haggerty, President at Maryland Oncology Hematology. “With her focus on new surgical advancements in breast cancer treatment, Dr. Plate will be a great addition to our breast cancer team as we seek to deliver the best breast cancer treatment in the Maryland Region.”

Cynthia Plate M.D. F.A.C.S is board-certified in general surgery and is a breast care specialist. She previously worked with Adventist HealthCare Medical Group.

Dr. Plate graduated from Howard University College of Medicine and completed her internship and residency at Howard University Hospital

“Specializing in women’s breast health, I’m committed to providing my patients with exceptional and compassionate care,” said Dr. Plate. “I’m thrilled to join the MOH team where we can continue to deliver leading-edge cancer care to our community.”

Dr. Plate is currently seeing patients at MOH’s Silver Spring White Oak Cancer Center office. Timely appointments are available for newly referred patients, typically within 24 hours, to provide a high level of support and prompt access to care. Please call 301-933-3216 to make an appointment

 

About Maryland Oncology Hematology

 

Maryland Oncology Hematology is an affiliate of The US Oncology Network (The Network). This

collaboration unites MOH with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH participates in clinical trials through US Oncology Research, which has played a role in more than 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.

 

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

 

Media Contacts:

 

Mark W Lamplugh Jr

The US Oncology Network

(561) 762-9729

mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Maryland Oncology Hematology to Open a New Cancer Center in Annapolis, MD

MOH’s new state-of-the-art facility will provide community cancer care to patients throughout the Annapolis area.

Beltsville, MD (10/28/20) – Maryland Oncology Hematology (MOH), a 48-physician privately-owned practice specializing in the diagnosis and treatment of cancer, announced it is opening its 13th location in Annapolis, MD. This new state-of-the-art facility will allow patients in Annapolis and the surrounding areas to access high-quality cancer care in a convenient community setting close to home. Maryland Oncology Hematology is now accepting appointments and will start seeing patients at the Annapolis office beginning November 2nd.

 

“With the opening of this new office, MOH will be providing the highest quality cancer care to the Annapolis community,” said Joseph Haggerty MD, Practice President, Maryland Oncology Hematology. “Patients will be able to receive leading-edge cancer care without having to travel long distances.”

 

Maryland Oncology Hematology in Annapolis will provide advanced care and comprehensive services including medical oncology, hematology, genetic risk assessment, and clinical research. Working as an independent practice allows MOH physicians the freedom to tailor care to each patient’s unique diagnosis. With one of the largest and most active clinical research programs conducted by a private practice in the state, MOH offers to its patients, among other things, the opportunity to participate in Phase I-IV clinical trials.

 

The multi-disciplinary team at the Annapolis location will deliver the latest in advanced, integrative cancer treatment. MOH is proud to announce that the following physicians will provide care at the new office:

 

Ravin J. Garg, MD

Peter R. Graze, MD

Stuart E. Selonick, MD

Jason D. Taksey, MD

Jeanine L. Werner, MD

 

 

MOH is further pleased to announce that Benjamin Bridges, MD, Adam J. Goldrich, MD, Carol K. Tweed, MD, and David E. Weng, MD will also be joining its team. These physicians will be temporarily practicing out of MOH’s office in Clinton, Maryland.

 

The MOH Annapolis office is located at 810 Bestgate Rd, Suite 400, Annapolis, MD, 21401. Physicians, patients, and family members can call 410.897.6200 to arrange a visit, consultation, or to make an appointment. The MOH Clinton office is located at 8926 Woodyard Rd #101 Clinton, MD 20735. Physicians, patients, and family members can call 301-812-3900 arrange a visit, consultation, or to make an appointment.

 

About Maryland Oncology Hematology

 

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 48 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in oncology & hematology services, cancer genetic risk assessment, clinical trials and research. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

 

 

 

Media Contacts

Mark Lamplugh

Maryland Oncology Hematology

561-762-9729

Mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

PRESS RELEASE: Maryland Oncology Hematology is Now Offering Advanced Radiation Services

Maryland Oncology Hematology is Partnering with Adventist HealthCare to Offer Comprehensive Care that Includes Advanced Radiation Services at the White Oak Cancer Center

Dr. Luqman Dad will lead The Center of Advanced Radiation Oncology and provide state-of-the-art radiation services and technologies to patients in the region.

Maryland, October 20, 2020 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has partnered with Adventist HealthCare to open The Center for Advanced Radiation Oncology at White Oak Cancer Center.

Led by radiation oncologist Luqman Dad, MD, the Center for Advanced Radiation Oncology at White Oak will work alongside the team at Maryland Oncology Hematology to offer compassionate, patient-centered, state-of-the-art radiation therapy. The center will offer seamless delivery of high-quality precise treatment by expert specialists, providing some of the latest in techniques and technologies, including: SBRT, IMRT, IGRT, SRS, and Brachytherapy, along with access to hyperbaric oxygen chamber for late toxicities and radiosensitization of recurrent tumors. The Center for Advanced Radiation Oncology will be located in the White Oak Cancer Center, where patients can have access to a comprehensive multidisciplinary approach to cancer including medical oncology/hematology, radiation oncology, surgical oncology, PET/CT imaging, genetics, research, nutrition, palliative care, social work, physical, occupational and speech rehabilitation.

Dr. Dad brings years of leadership and academic study to The Center of Advanced Radiation Oncology at White Oak Cancer Center. Born at the original Washington Adventist Hospital, Dr. Dad grew up just down the road from the White Oak Cancer Center and attended Paint Branch High School. He completed his undergraduate and medical studies at Boston University. In 2011, Dr. Dad returned to Maryland following the completion of his post-graduate training in Radiation Oncology at Roswell Park Cancer Institute. The Washington Metropolitan area remains close to his heart.

Medical Director, Radiation Oncology

 

“I’m proud to live in a community with great culture, diversity, and opportunities where we can make a tremendous impact and deliver top-notch cancer care,” said Dr. Dad, Medical Director at The Center for Advanced Radiation at White Oak. “At The Center for Advanced Radiation, we’re excited to provide personalized, innovative cancer treatments using the latest technologies.”

 

Dr. Luqman Dad serves as the Medical Director at The Center for Advanced Radiation Oncology at White Oak. He performs numerous procedures to treat patients at all stages of cancer care and is skilled in advanced radiation techniques, including stereotactic body radiation therapy (SBRT), intracranial radiosurgery (SRS), proton beam therapy, gynecologic high-dose rate (HDR) brachytherapy, and more. He is board certified in radiation oncology.

Through the affiliate partnership with the Maryland Proton Treatment Center (MPTC), Dr. Dad has access to this new advanced treatment that is only available in select cancer centers nationwide. Dr. Dad is able to see patients at the White Oak Cancer Center and collaborate with the team at MPTC if proton beam treatment is indicated for the patient.

Dr. Dad has a special interest in breast, prostate, lung, head and neck, gastrointestinal, lymphoma, and central nervous system malignancies. He has served as a lead physician in helping develop national clinical practice parameters for SBRT, as well as principal investigator on industry-sponsored clinical trials. Dr. Dad is an active member of the American Society for Radiation Oncology (ASTRO), where he serves on national committees and helps ASTRO in the global outreach of radiation oncology to underserved regions of the world.

“I’m looking forward to the opportunity to partner with Maryland Oncology Hematology to provide cutting-edge, evidencebased, patient-centered care to this community,” said Dr. Dad. “I believe that the dynamic location, supported by strong infrastructure and the future vision for the White Oak corridor as a hub for science and technology that will place The White Oak Radiation Oncology Program in a position for tremendous growth and success.”

Opening in November, The Center for Advanced Radiation Oncology at White Oak Cancer Center will be located at 11886 Healing Way Suite 101, Silver Spring, MD, 20904. To learn more or to schedule an appointment, visit MarylandOncology.com or call 301.343.3892.

 

About Maryland Oncology Hematology

 

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

 

 

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

To be distributed to local media:

Practice: Maryland Oncology Hematology

Contact: Mark Lamplugh

Phone : 561-762-9729

Email : mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

United in Healing with The US Oncology Network - Maryland Oncology Hematology